These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33361385)

  • 1. Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS.
    Tsaktanis T; Beyer T; Nirschl L; Linnerbauer M; Grummel V; Bussas M; Tjon E; Mühlau M; Korn T; Hemmer B; Quintana FJ; Rothhammer V
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33361385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Aryl Hydrocarbon Receptor-Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis.
    Cirac A; Tsaktanis T; Beyer T; Linnerbauer M; Andlauer T; Grummel V; Nirschl L; Loesslein L; Quintana FJ; Hemmer B; Rothhammer V
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34301821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
    Brandt AU; Sy M; Bellmann-Strobl J; Newton BL; Pawling J; Zimmermann HG; Yu Z; Chien C; Dörr J; Wuerfel JT; Dennis JW; Paul F; Demetriou M
    JAMA Neurol; 2021 Jul; 78(7):842-852. PubMed ID: 33970182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging spinal cord atrophy in progressive myelopathies: HTLV-I-associated neurological disease (HAM/TSP) and multiple sclerosis (MS).
    Azodi S; Nair G; Enose-Akahata Y; Charlip E; Vellucci A; Cortese I; Dwyer J; Billioux BJ; Thomas C; Ohayon J; Reich DS; Jacobson S
    Ann Neurol; 2017 Nov; 82(5):719-728. PubMed ID: 29024167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.
    Mina Y; Azodi S; Dubuche T; Andrada F; Osuorah I; Ohayon J; Cortese I; Wu T; Johnson KR; Reich DS; Nair G; Jacobson S
    Neuroimage Clin; 2021; 30():102680. PubMed ID: 34215150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.
    Huber AK; Wang L; Han P; Zhang X; Ekholm S; Srinivasan A; Irani DN; Segal BM
    Neurology; 2014 Oct; 83(17):1500-7. PubMed ID: 25253754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
    Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
    Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
    Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
    Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.
    Filippi M; Preziosa P; Barkhof F; Chard DT; De Stefano N; Fox RJ; Gasperini C; Kappos L; Montalban X; Moraal B; Reich DS; Rovira À; Toosy AT; Traboulsee A; Weinshenker BG; Zeydan B; Banwell BL; Rocca MA
    JAMA Neurol; 2021 Mar; 78(3):351-364. PubMed ID: 33315071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Kearney H; Miszkiel KA; Yiannakas MC; Altmann DR; Ciccarelli O; Miller DH
    Mult Scler; 2016 Jun; 22(7):910-20. PubMed ID: 26432854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data.
    Sampat MP; Berger AM; Healy BC; Hildenbrand P; Vass J; Meier DS; Chitnis T; Weiner HL; Bakshi R; Guttmann CR
    AJNR Am J Neuroradiol; 2009 Oct; 30(9):1731-9. PubMed ID: 19696139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
    Silber E; Semra YK; Gregson NA; Sharief MK
    Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.
    Dou L; Poitevin S; Sallée M; Addi T; Gondouin B; McKay N; Denison MS; Jourde-Chiche N; Duval-Sabatier A; Cerini C; Brunet P; Dignat-George F; Burtey S
    Kidney Int; 2018 Apr; 93(4):986-999. PubMed ID: 29395338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of aryl hydrocarbon receptor agonists in human samples.
    Rothhammer V; Borucki DM; Kenison JE; Hewson P; Wang Z; Bakshi R; Sherr DH; Quintana FJ
    Sci Rep; 2018 Mar; 8(1):4970. PubMed ID: 29563571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.